DEBBANE RAYMOND 4

What Happened Raymond Debbane, a director of Lexicon Pharmaceuticals (LXRX), made three open-market purchases (code P) totaling 268,497 shares between Feb 13 and Feb 18, 2026. The purchases were reported as: 57,952 shares on 2026-02-13 at a weighted-average price of $1.31 ($75,877), 76,857 shares on 2026-02-17 at $1.31 ($100,544), and 133,688 shares on 2026-02-18 at $1.32 (~$176,468). These are outright purchases (buying stock), which investors often view as a more direct sign of insider accumulation than routine sales.

Key Details

• Transaction type: Open-market purchases (reporting code P).
• Dates and reported prices:
  • 2026-02-13: 57,952 shares at weighted avg $1.31 (actual prices ranged $1.29–$1.31) — Footnote F1.
  • 2026-02-17: 76,857 shares at weighted avg $1.31 (range $1.295–$1.31) — Footnote F2.
  • 2026-02-18: 133,688 shares at weighted avg $1.32 (range $1.315–$1.32) — Footnote F3.
• Total purchased: 268,497 shares for approximately $352,889.
• Shares owned after the transaction: Not specified in the information provided in this summary (check the Form 4 for post-transaction beneficial ownership).
• Filing date: Form filed 2026-02-18. Note the Feb 13 purchase was reported on Feb 18; Form 4 is generally due within two business days of the transaction, so the Feb 13 entry appears to have been reported after the two-business-day window.
• Footnotes: Each lot reports a weighted-average price with a disclosed price range and an undertaking to provide full per-trade detail upon request.

Context

• These are direct purchases (not option exercises, grants, or gifts), so they represent the insider buying shares rather than selling or receiving awards. That can be of interest to retail investors, but it does not prove future company performance.
• No indication here of a 10b5-1 plan, cashless exercise, or tax-withholding—read the full Form 4 for any additional filing details or disclosures.